Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Byrd

Showing results (71-80 of 681) with videos related to

Pageof 69
Sort By:
Current Opinion in Oncology|October 2, 2007
Flavopiridol in the treatment of chronic lymphocytic leukemiaBeth A Christian, Michael R Grever, John C Byrd, et al.
Chest|September 13, 2002
Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromesDonald L Helman, John C Byrd, Noel C Ales, et al.
Cancer|April 5, 2002
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient populationJeremy G Perkins, Joseph M Flynn, Robin S Howard, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 6, 2007
Community-based phase II trial of PCR for CLL/SLL patientsNeil E Kay, Tait D Shanafelt, John C Byrd, et al.
Journal of Pharmaceutical Sciences|August 28, 2007
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatmentXiaobin Zhao, Jianmei Wu, Natarajan Muthusamy, et al.
Best Practice & Research. Clinical Haematology|August 21, 2007
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemiaMichael R Grever, David M Lucas, Amy J Johnson, et al.
Cell Reports|September 30, 2014
NF-κB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cellsDavid J Wang, Nivedita M Ratnam, John C Byrd, et al.
JAMA Dermatology|November 29, 2016
Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic LeukemiaAbraham M Korman, Justin G Hastings, John C Byrd, et al.
Oncoimmunology|July 30, 2016
A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cellsGayathri Natarajan, Steve Oghumu, Cesar Terrazas, et al.
Annals of Hematology|August 20, 2016
Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemiaEleshia J Morrison, Joseph M Flynn, Jeffrey Jones, et al.
Pageof 69

Showing results (71-80 of 681) with videos related to

Sort By:
Pageof 69
Current Opinion in Oncology|October 2, 2007
Flavopiridol in the treatment of chronic lymphocytic leukemiaBeth A Christian, Michael R Grever, John C Byrd, et al.
Chest|September 13, 2002
Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromesDonald L Helman, John C Byrd, Noel C Ales, et al.
Cancer|April 5, 2002
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient populationJeremy G Perkins, Joseph M Flynn, Robin S Howard, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 6, 2007
Community-based phase II trial of PCR for CLL/SLL patientsNeil E Kay, Tait D Shanafelt, John C Byrd, et al.
Journal of Pharmaceutical Sciences|August 28, 2007
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatmentXiaobin Zhao, Jianmei Wu, Natarajan Muthusamy, et al.
Best Practice & Research. Clinical Haematology|August 21, 2007
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemiaMichael R Grever, David M Lucas, Amy J Johnson, et al.
Cell Reports|September 30, 2014
NF-κB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cellsDavid J Wang, Nivedita M Ratnam, John C Byrd, et al.
JAMA Dermatology|November 29, 2016
Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic LeukemiaAbraham M Korman, Justin G Hastings, John C Byrd, et al.
Oncoimmunology|July 30, 2016
A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cellsGayathri Natarajan, Steve Oghumu, Cesar Terrazas, et al.
Annals of Hematology|August 20, 2016
Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemiaEleshia J Morrison, Joseph M Flynn, Jeffrey Jones, et al.
Pageof 69